The case for & against
Bull & Bear analysis
Bullish
ASP Isotopes Inc. (NASDAQ: ASPI) is a company specializing in the production of isotopes, focusing on nuclear medicine, electronics, and nuclear energy sectors. The firm operates multiple facilities, primarily in South Africa, leveraging proprietary technologies to address critical supply shortages in high-demand isotopes such as Silicon-28, Ytterbium-176, and Carbon-14. As an emerging player in the isotopes market, ASP Isotopes aims to capitalize on increasing global demands driven by advances in medical treatments and semiconductor applications.
Bull says
- ↑Revenue 2025: $23.8M (+480% YoY) driven by radiopharmacy
- ↑Cash & equivalents $333M (liquidity score 1.05) funds expansions
- ↑Radiopharmacy revenue $5.7M (+46% YoY) underpins core growth
- ↑Signed contracts ensure $2.5M+ annual Carbon-14 revenue
- ↑High revisions score indicates growing analyst confidence
- ↑First Si-28, Yb-176, C-14 shipments slated for mid-2026
Bear says
- ↓YTD net loss $34.9M driven by 84% higher Opex
- ↓Elevated leverage raises refinancing risk amid cost pressures
- ↓Negative earnings yield and weak profitability factors persist
- ↓Regulatory approvals uncertainty may delay revenue recognition
- ↓Short interest 3.78% signals investor skepticism
- ↓Operational start-up delays heighten execution risk
Investment themes with ASPI
Uranium↑ +1.35%
TECK · BOE · URG
Nuclear↓ -0.11%
Nuclear energy production and related companies
NXE · EU · UUUU
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Animal Spirits 2026↓ -2.81%
ASTS · SERV · UUUU
Earnings Call · Q3 2025 · Mgmt. Guidance
Updated 09-11-2026neutral
Transcript signals
Bull points
- we raised about $41.7 million of capital into the business to facilitate acquisitions and growth.
- We've made two acquisitions to date, which I think are highly strategic to both the United States at large and also ASPI QLE.
- we expect to disclose the exact nature of these assets before the end of the year.
Bear points
- So, we're not at this stage changing guidance that we've given before, acknowledging that things have taken slightly longer than our initial estimations to bring into service, which affects our forecasts and revenue indications.
- They don't want their competitors knowing where they're buying their isotopic products from, what enrichment levels they are, what they're paying for them. So it does make it difficult to give sort of the kind of data that investment analysts like to feed their projected models.
- Year-to-date total operating expenses increased by 16.5 million or 84% from 19.7 million in 2024 to 36.2 million in 2025.
Read full transcript analysis ›